Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden

Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems’ bu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marín, Gustavo Horacio, Marín, Lupe, Haag, Griselda Octavia, Risso, Paula, Errecalde, Jorge Oscar
Formato: Articulo
Lenguaje:Inglés
Publicado: 2018
Materias:
Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/162137
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-162137
record_format dspace
spelling I19-R120-10915-1621372023-12-30T04:06:37Z http://sedici.unlp.edu.ar/handle/10915/162137 Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden Marín, Gustavo Horacio Marín, Lupe Haag, Griselda Octavia Risso, Paula Errecalde, Jorge Oscar 2018 2023-12-29T16:53:28Z en Ciencias Médicas Biosimilars Anaemia Chronic Failure Renal Cost Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems’ budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD. Facultad de Ciencias Médicas Consejo Nacional de Investigaciones Científicas y Técnicas Comisión de Investigaciones Científicas de la provincia de Buenos Aires Articulo Articulo http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf 96-99
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
spellingShingle Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
Marín, Gustavo Horacio
Marín, Lupe
Haag, Griselda Octavia
Risso, Paula
Errecalde, Jorge Oscar
Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
topic_facet Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
description Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems’ budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD.
format Articulo
Articulo
author Marín, Gustavo Horacio
Marín, Lupe
Haag, Griselda Octavia
Risso, Paula
Errecalde, Jorge Oscar
author_facet Marín, Gustavo Horacio
Marín, Lupe
Haag, Griselda Octavia
Risso, Paula
Errecalde, Jorge Oscar
author_sort Marín, Gustavo Horacio
title Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_short Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_full Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_fullStr Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_full_unstemmed Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_sort erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
publishDate 2018
url http://sedici.unlp.edu.ar/handle/10915/162137
work_keys_str_mv AT maringustavohoracio erythropoietintreatmentinchronicrenalfailureanaemiabiosimilaroptionintherationaluseofmedicineprocessinordertoreducedpublichealtheconomicburden
AT marinlupe erythropoietintreatmentinchronicrenalfailureanaemiabiosimilaroptionintherationaluseofmedicineprocessinordertoreducedpublichealtheconomicburden
AT haaggriseldaoctavia erythropoietintreatmentinchronicrenalfailureanaemiabiosimilaroptionintherationaluseofmedicineprocessinordertoreducedpublichealtheconomicburden
AT rissopaula erythropoietintreatmentinchronicrenalfailureanaemiabiosimilaroptionintherationaluseofmedicineprocessinordertoreducedpublichealtheconomicburden
AT errecaldejorgeoscar erythropoietintreatmentinchronicrenalfailureanaemiabiosimilaroptionintherationaluseofmedicineprocessinordertoreducedpublichealtheconomicburden
_version_ 1807222289482121216

Ejemplares similares